Xanthochromia - A QC to aid in the monitoring of Subarachnoid Haemmorrhage
Cambridge Life Sciences in conjunction with ADP is now able to offer Xanthochromia - a Cerebral Spinal Fluid (CSF) QC, intended for use as a quality control to monitor the performance of laboratory screening of CSF for the presence of haemoglobin and/or bilirubin.
Available as a frozen liquid stable format, single or bi-level, 1.0 or 0.5ml vials.
Typical values Level 1, NOA 0.100 ......NBA 0.008, Level 2 NOA 0.160.......NBA 0.045
Please contact us if you would like further information.
New CLS Paracetamol Sera Calibrators for improved accuracy and sensitivity
As proof that CLS really does listen to its customers and following customer feedback and evaluation, Cambridge Life Sciences is now pleased to be able to offer new Paracetamol Sera Calibrators to go alongside the popular K8002 and K8003 Paracetamol Kits. The key features include:-
• Human sera based calibrators to improve accuracy and sensitivity
• Sensitivity: <3mg/L (0.02mmol/L)
• Measurement range: 3 - 378mg/L (0.02 - 2.50mmol/L)
• Calibration frequency: 168 hours
• Liquid ready to use
Each Paracetamol Sera Calibrator Kit contains 4 x 0 mmol/L (0 mg/L) and 4 x 2mmol/L (302 mg/L) in 0.5ml vials. Please find attached a datasheet which features more information on sensitivity, precision, linearity and calibration stability. All the other claims for both products remain unchanged.
Protocols are available for most clinical chemistry automates. A datasheet is available here
Please contact us if you would like further information or an IFU specific to your analyser.
Dr Suzanne Turner in the Department of Pathology is the coordinator of a successful bid for a €4 million European Union Marie Curie Innovative Training Network
This ETN is embedded into an established international research programme; The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (ERIA; www.erialcl.net) is an existing and functional network of 13 partners, which will cosset and nurture a cohort of early stage researchers to become confident, competent, independent and well-connected European scientists with excellent career perspectives. ERIA was instigated to coordinate research into ALK-related malignancies to facilitate the development of less-toxic and more efficacious therapies. ALK is increasingly recognised as a prevalent oncogene in a number of human malignancies and therefore poses a prominent clinical problem, which requires coordinated research into its oncogenic mechanisms. ERIA now conducts a collaborative multidisciplinary research programme at the interface of biomedical and bio-mechanistic approaches, which will be an excellent environment to train the next generation of European scientists. The 15 recruited fellows will be incorporated into international academic study groups (all partners of the ERIA network) to perform high calibre research and also will be exposed to environments from other sectors to broaden their experience. Secondments will include technical training within individual laboratories and SMEs (TissueGnostics, Galkem, Cambridge Life Sciences, Sofigen and Varionostics) as well as large Pharma (Roche). Training through research will be complemented with a balanced programme of transferable skills and access to local courses. The training of each fellow will be guided by a personal career development plan and supervised by a PhD committee panel. The primary goal of the network is to train the recruited fellows by participation in an internationally competitive research programme and integrating them into an international network. Thereby providing competence in state-of-the-art research and development at the forefront of translational science.
With a score of 95.4 the ETN made it into the top 6.3 % out of more than 1,300 proposals to obtain an invitation for funding. This makes European Training Networks one of the most competitive funding opportunities available within HORIZON2020. “With ERIA we have based this proposal on an existing network of academic research collaboration, which will now be reinforced through the incorporation of several companies. I hope this will speed up the translation of our research into novel and improved therapies” said Dr Suzanne Turner. The core focus of the consortium which is called ALKATRAS: Break free from cancer, is to investigate mechanisms employed by the ALK oncogene to induce a variety of cancers including lymphoma, neuroblastoma and lung cancer. In doing so, it is hoped that novel therapeutic targets will be discovered and treatments for these developed together with the assistance of a number of companies based within Europe.
BlueDiver range of products from D-Tek
The BlueDiver Instrument is a compact and innovative machine which processes the strips with ready-to-use reagents provided in individual cartridges.
This “no pump – no liquid handling” machine presents many advantages such as a time-effectiveness (results are obtained in only 1 hour), limited maintenance (no pumps/tubes to be serviced or replaced), space-effectiveness (BlueDiver Instrument is as compact as a microwave oven)
Moreover the specific architecture of the BlueDiver Instrument and the standardised test procedures allow the testing of 24 different samples on 24 similar or completely different test strips. This fact combined with the tremendous reduction of processing time gives maximum flexibility to laboratory technicians.
The BlueDiver Instrument has been conceived to comply with the CE IVD recommendations and major laboratory accreditation requirements.
- Space saving - As compact as a microwave oven
- No risk of contamination - No pumps, no liquid handling, no dead volume, works with ready to use and disposable reagents cartridges
- Flexible - From 1 to 24 similar or different assays can be run simultaneously
- Easy to use - Simply load the Immunodot Strips, the reagent cartridges, the patient
samples, press on and follow the test processing data through a user friendly touch screen
- Automatic check-in - Through a barcode association between the strips and the reagent cartridges
- Unequalled short testing time - Thanks to an Innovative processing principle
- Open system - Compatible with the whole range of D-Tek’s Immunodot products and with a large panel of other Immunoassays
A video of the BlueDiver instrument in action can be found here here
BlueDiver Dot kits are composed of 24 nitrocellulose strips on which the antigens have been coated in a dot-shaped format. One strip allows the testing of one patient for many different autoantibodies in the same run. The test is based on a classical Enzyme ImmunoAssays (EIA).
In addition to the antigens, each strip possesses two built-in reactive controls :
- The first one, the Reaction Control (RC), controls the validity of the test : its coloration proves that the clinician has added the patient serum and that the test has functioned correctly.
- The second one, the Cut-Off Control (CO), allows the interpretation of the test : any color intensity equal to or below that of the cut-off is considered negative, any color intensity superior to that of the cut-off is considered positive.
The BlueDiver Dot are automated on the BlueDiver Instrument. The complete processing time lasts just 1 hour. The results can be interpretated by sight or a semi-quantification can be obtained thanks to the BlueScan scanner and the Dr DOT software (minimum version 3).
- Indication : Suitable for small to high throughput laboratories or hospitals
- Support of reaction : nitrocellulose (strip)
- Volume of sample needed : 10 µl
- Number of autoantibodies detected : up to 12
- Test duration : 1h
- Testing : BlueDiver Instrument
- Reading : Visual or BlueScan + Dr DOT software (minimum version 3)
- Results : Qualitative or semi-quantitative
- Controls : Positive and negative built-in controls
For more information on the range of kits available, please contact us